Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
3939 studies found for:    novartis
Show Display Options
Rank Status Study
21 Completed
Has Results
Safety and Immune Response of Novartis MenACWY-CRM Conjugate Vaccine When Given to Healthy Toddlers
Condition: Meningococcal Infections
Interventions: Biological: MenACWY-CRM + MMRV;   Biological: MMRV;   Biological: MenACWY-CRM
22 Active, not recruiting Study to Allow Access to Imatinib for Patients Who Are on Imatinib Treatment in a Novartis-sponsored Study and Are Benefiting From the Treatment as Judged by the Investigator
Condition: GIST and CML
Intervention: Drug: STI571
23 Completed
Has Results
A Study to Evaluate Safety and Immune Response of Novartis Meningococcal ACWY Vaccine In Infants
Condition: Meningitis, Meningococcal
Interventions: Biological: Meningococcal ACWY Conjugate Vaccine;   Biological: DTaP-IPV-HBV;   Biological: Hib;   Biological: Rotavirus;   Biological: Pneumococcal 7-valent Conjugate Vaccine;   Biological: HAV;   Biological: MMR-V;   Biological: DTaP
24 Completed
Has Results
Immunogenicity, Safety and Lot to Lot Consistency of Novartis Meningococcal B Recombinant Vaccine When Administered With Routine Infant Vaccinations to Healthy Infants
Condition: Serogroup B Meningococcal Meningitis
Interventions: Biological: Serogroup B meningococcal Vaccine lot 1 (rMenB Lot 1);   Biological: Serogroup B meningococcal Vaccine lot 2 (rMenB Lot 2);   Biological: Serogroup B meningococcal Vaccine lot 3 (rMenB Lot 3);   Biological: Infanrix Hexa;   Biological: Menjugate;   Biological: Prevenar
25 Completed
Has Results
Safety, Tolerability and Immunogenicity of Novartis Meningococcal B Recombinant Vaccine Administered to Healthy Adolescents According to Different Vaccination Schedules
Condition: Meningococcal Disease
Interventions: Biological: rMenB+OMV NZ;   Biological: Placebo
26 Active, not recruiting An Open Label Multi-center Extension Study to Evaluate Long-term Safety/ Tolerability of Dovitinib in Patients With Solid Tumors Who Continue to Receive Treatment With Dovitinib (TKI258) in Novartis-sponsored Single Agent Dovitinib Studies Which Fulfilled the Requirements for the Primary Objective
Condition: Solid Tumors
Interventions: Drug: dovitinib;   Drug: fulvestrant
27 Completed
Has Results
Extension Study of V72P13 to Evaluate the Safety, Tolerability and Immunogenicity of Novartis Meningococcal B Recombinant Vaccine When Administered as a Booster or as a Two-dose Catch-up to Healthy Toddlers
Condition: Meningococcal Disease
Interventions: Biological: 1a - rMenB+OMV NZ and routine vaccines;   Biological: 1b - rMenB+OMV NZ and routine vaccines;   Biological: 2a - Routine and rMenB+OMV NZ vaccines;   Biological: 2b - rMenB+OMV NZ and routine vaccines;   Biological: 3a - rMenB+OMV NZ and routine vaccines;   Biological: 3b - 1 dose of rMenB+OMV NZ plus routine infant vaccinations;   Biological: 4a- rMenB+OMV NZ and routine vaccines;   Biological: 4b - rMenB+OMV NZ and routine vaccines
28 Active, not recruiting Study to Allow Access to Single Agent Panobinostat for Patients Who Are on s.a. Panobinostat Treatment in a Novartis-sponsored Study and Are Benefiting From the Treatment as Judged by the Investigator
Condition: Hematologic Neoplasms
Intervention: Drug: Panobinostat
29 Active, not recruiting Safety and Immunogenicity of Novartis Meningococcal Group B Vaccine When Administered Concomitantly With Novartis MenACWY Conjugate Vaccine to Healthy Infants
Condition: Meningococcal Disease
Interventions: Biological: rMenB+OMV and MenACWY;   Biological: rMenB+OMV;   Biological: MenACWY
30 Recruiting Roll-over Study to Allow Access to Certinib (LDK378) for Patients Who Are on Ceritinib Treatment in a Novartis-sponsored Study
Condition: ALK Positive Malignancies
Intervention: Drug: ceritinib
31 Completed
Has Results
Study to Evaluate the Safety of Novartis MenACWY Conjugate Vaccine When Administered With Routine Infant Vaccinations to Healthy Infants
Conditions: Meningitis;   Meningococcal Infection
Interventions: Biological: MenACWY-CRM197;   Biological: DTaP (Diptheria, Tetanus, Pertussis) Vaccine;   Biological: Hib (Haemophilus influenza b) Vaccine;   Biological: IPV (Inactivated Polio Vaccine) Vaccine;   Biological: Pneumococcal conjugate Vaccine;   Biological: MMR (Measles, Mumps, and Rubella) Vaccine;   Biological: Varicella Vaccine;   Biological: Hepatitis A Virus
32 Completed Safety and Immunogenicity of Novartis Meningococcal B Vaccine When Administered to Immunocompromised Children and Adolescents Compared to Healthy Subjects
Condition: Meningococcal Disease
Intervention: Biological: rMenB+OMV
33 Completed
Has Results
A Phase 3b Study to Assess the Safety of Novartis Meningococcal B Recombinant Vaccine When Administered in Healthy At-risk Adults
Conditions: Meningococcal Disease;   Meningococcal Meningitis
Intervention: Biological: Recombinant meningococcal B + OMV NZ
34 Completed
Has Results
Safety and Immunogenicity of Novartis Meningococcal ACWY Conjugate Vaccine in Healthy Children Aged 12-59 Months.
Condition: Meningococcal Meningitis
Interventions: Biological: MenACWY-CRM conjugate vaccine, adjuvanted;   Biological: MenACWY polysaccharide vaccine;   Biological: MenACWY-CRM conjugate vaccine, unadjuvanted
35 Completed
Has Results
A Phase 3b, Single-Center, Open-label Study to Assess the Immunogenicity and Safety of Novartis Meningococcal B Recombinant Vaccine When Administered at a 0, 2-Month Schedule in Healthy At-Risk Adults Aged 18 to 65 Years Inclusive.
Condition: Prevention of the Meningococcal Disease
Intervention: Biological: rMenB+OMV NZ
36 Completed Bioequivalence of Vildagliptin Tablet Manufactured in China Compared to Imported Vildagliptin Tablet in Chinese Healthy Volunteers
Condition: Healthy
Intervention: Drug: Vildagliptin (LAF237)
37 Completed
Has Results
Persistence Of Antibody Responses Among Children Who Previously Received Novartis MenACWY Conjugate Vaccine or Meningococcal C Conjugate Vaccine
Condition: Meningococcal Disease
Intervention: Biological: MenACWY-CRM
38 Completed A 16 Week Evaluation of the Novartis Health Management Tool (HMT) in Age Related Macular Degeneration (AMD)
Condition: Age Related Macular Degeneration (AMD)
Intervention: Device: Health Management Tool (HMT)
39 Completed
Has Results
Safety and Immunogenicity Evaluation After One or Two Doses of Novartis Meningococcal ACWY Conjugate Vaccine in Healthy Infants and Toddlers
Condition: Meningococcal Meningitis
Interventions: Biological: MenACWY-CRM197 (two doses);   Biological: MenC;   Biological: PCV7;   Biological: DTPa-IPV-HepB-Hib;   Biological: MenACWY-CRM197 (one dose)
40 Completed
Has Results
Safety and Immunogenicity of One Dose of Novartis' Meningococcal ACWY-CRM Vaccine and GlaxoSmithKline Biologicals' Meningococcal ACWY-TT Vaccine in Healthy Toddlers
Condition: Meningococcal Disease
Interventions: Biological: MenACWY-CRM;   Biological: MenACWY-TT

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.